Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

EAG Acquires PTRL West and PTRL Europe

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
EAG adds new division to serve high-end analytical testing needs of the chemical and pesticide industry.

Evans Analytical Group, Inc. (EAG) has announced that it has acquired PTRL West, Inc. (Hercules, CA) and PTRL Europe GmbH (Ulm, Germany).

PTRL West and PTRL Europe will continue to operate under their current names and locations as divisions of EAG. Financial terms of the transaction were not disclosed.

PTRL has created a world-wide business serving the regulatory testing needs of the leading international agrochemical companies.

PTRL provides specialized services in Analytical Chemistry and Residue Analysis, Environmental Fate and Metabolism to assist in the required regulatory testing to bring new pesticides to market and to perform testing required for re-registrations of compounds.

PTRL serves the regulatory requirements of the U.S. EPA, U.S. FDA, EU, REACH, OECD and JMAFF governmental agencies.

The work conducted at the PTRL facilities is in compliance with Good Laboratory Practices (GLP) for the Agrochemical industry and complements our GLP work for the pharmaceutical industry conducted within our EAG Life Sciences Division.

With a continuing commitment to scientific expertise, accuracy of chemical analysis, investment in advanced instrumentation and technologies, and building long-term business partnerships with customers, PTRL has established itself as the premier laboratory for executing challenging analytical work.

For over 20-years, customers from the U.S, Europe and Japan have relied on PTRL as a trusted partner in the complex, regulated process of bringing new pesticides to market.

Harry Davoody, CEO of EAG states "Both PTRL and EAG value our customer relationships first and foremost. The acquisition of PTRL was very compelling to EAG and fits into EAG's overall growth strategy in offering a broader range of high-end analytical services for new and existing customers of EAG. EAG's different divisional strengths complement each other with their best-in-class subject matter expertise which is highly valued by our specialized customers."

Dr. Luis Ruzo, co-founder and Head of PTRL West, affirmed that "PTRL is pleased to become part of an organization as well-regarded as EAG. This merger is very important to PTRL, providing us with additional resources from a solid long-standing company which supports our efforts to continue to grow our labs and our capabilities for our valued customers."

Dr. Thomas Class, co-founder and Head of PTRL Europe, noted "PTRL carefully selected EAG knowing that PTRL and its team will be part of EAG's future growth engine beyond EAG's existing markets. EAG recognized the potential in the agrochemical segment and is very committed to further investing in our business going forward."

Virginia M. Turezyn, SVP of Business Development and Strategy, comments "The agrochemical market sector has been on our radar for some time and we were pleased to have the best-in-class management and team at PTRL to serve as the cornerstone for EAG's entry into this industry."

Neal McCarthy, Managing Director of Fairmount Partners, who assisted PTRL and EAG in this transaction commented "With the acquisition of PTRL, EAG has added the finest agrochemical lab in North America and Europe, and with Dr. Luis Ruzo and Dr. Thomas Class and the other PTRL scientists, EAG adds world class experts in the field of agrochemicals, to its impressive roster of scientific talent."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos